Metformin and ACLR Muscle Recovery

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age40+
SponsorUniversity of Utah

About this trial

The purpose of this research study is to determine if Metformin taken after anterior cruciate ligament reconstruction (ACLR) surgery can decrease muscle fibrosis, cellular senescence and improve leg strength. ACL injury and surgery increase muscle collagen content and inflammation which slows the recovery of muscle and function and ultimately impacts the quality of life. Individuals enrolled in the study will be randomized to receive metformin (or placebo) for 4 months after surgery. The investigators will measure muscle strength and inflammatory markers in muscle biopsy samples after the intervention period. Investigators will also follow up with participants 8 months later to determine the lasting effects of the intervention.

Eligibility criteria

Qualifiers

Age between 40y and older

BMI: <30 kg/m2

Full thickness ACL tear

Less than 6 months between ACL injury and scheduled ACLR

Disqualifiers

Prior ACL tear in limb scheduled for reconstruction or current bilateral ACL tear

Total knee dislocation

Anticipated quadriceps ACLR grafts

Current infection near the lower limb

Trial design

Treatments tested in this trial

  • Metformin
  • Placebo

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators